ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS
Engineered nanoantibodies (single domain VHH antibodies) targeting TNF to restore endothelial barrier function in sepsis
- Sector
- Biotech
- Total capital
- $1.7M
- Federal grants
- $1.1M
- 5 awards · 2015–2018
- Rank in peer group#271 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $550K
- 4 awards · Veterans Affairs, Health and Human S
- Rank in Biotech#225 of 4373
- Granted patents
- 4
- 17 pending · first 2018
- Rank in peer group#35 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Effective Nanoantibodies as Promising Therapeutics for Treating Sepsis$225K
- Federal grantHealth and Human S · Phase I · Human Neural Stem Cells Engineered against oAβ-Induced Toxicity for Cell Therapy$225K
- Federal grantHealth and Human S · Phase I · Anti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimer’s Disease.$225K
- Federal grantHealth and Human S · Phase I · Adaptable and Automated Large-Scale Manufacturing of iPSC-Derived Cell Products$222K
- Federal grantHealth and Human S · Phase I · Generation and Characterization of Nanobodies Against beta-Amyloid$225K
- Federal contractHealth and Human S · TAS::75 0893::TAS Single Chain Antibodies As Renewable Capture Reagents$200K
- Federal contractHealth and Human S · TAS::75 0849::TAS R&d-other Sciences-eng Dev$200K
Show 2 earlier federal awards
- Federal contractHealth and Human S · SBIR Topic 269: Development Of Novel Protein Expression Technologies For Glycosylated Cancer Related Proteins$150K
- Federal contractVeterans Affairs · Small Purchase Data$295
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#35 · top 11%
- Linked publications#3 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 4 granted of 21- GrantedInduction Of Hepatocytes By Stem Cell Differentiation With RnaUSPTOUS 12,559,729
- PendingInduction Of Pancreatic Beta Cells By Stem Cell Differentiation With RnaUSPTOApplication 19213860
- GrantedInduction Of Pancreatic Beta Cells By Stem Cell Differentiation With RnaUSPTOUS 12,338,462
Show all 21 patent records
- Induction Of Hepatocytes By Stem Cell Differentiation With RnaFeb 24, 2026 · US 12,559,729Granted
- Induction Of Pancreatic Beta Cells By Stem Cell Differentiation With RnaSep 11, 2025 · Application 19213860Pending
- Induction Of Pancreatic Beta Cells By Stem Cell Differentiation With RnaJun 24, 2025 · US 12,338,462Granted
- Induction Of Neural Progenitor Cells, Oligodendrocyte Progenitor Cells, And Oligodendrocytes By Stem Cell Differentiation Using Landmark Transcription FactorsFeb 13, 2025 · Application 18811419Pending
- Induction Of Neural Progenitor Cells, Oligodendrocyte Progenitor Cells, And Oligodendrocytes By Stem Cell Differentiation Using Landmark Transcription FactorsOct 1, 2024 · US 12,104,171Granted
- Use Of Enzymes For Altering Ratios Of Partially Matched PolynucleotidesJan 4, 2024 · Application 18212605Pending
- Methods Of Achieving High Specificity Of Genome EditingJun 23, 2022 · Application 17259998Pending
- Use Of Enzymes For Altering Ratios Of Partially Matched PolynucleotidesMar 19, 2020 · Application 16532396Pending
- Novel Monomeric Yellow-green Fluorescent Protein From CephalochordateAug 1, 2019 · Application 16256973Pending
- Feeder-free Derivation Of Human-induced Pluripotent Stem Cells With Synthetic Messenger RnaDec 18, 2018 · US 10,155,929Granted
- Methods Of Achieving High Specificityof Genome EditingApplication 62697955Pending
- Induction Of Nerual Progenitor Cells, Oligodendrocyte Progenitor Cells, And Oligodendrocytes By Stem Cell Differentiation Using Landmark Transcription FactorsApplication PCTUS2018042027Pending
- Induction Of Nerual Progenitor Cells, Oligodendrocyte Progenitor Cells, And Oligodendrocytes By Stem Cell Differentiation Using Landmark Transcription FactorsApplication 62532246Pending
- Induction Of Pancreatic Beta Cells By Stem Cell Differentiation With RnaApplication 62423120Pending
- Induction Of Hepatocytes By Stem Cell Differentiation With RnaApplication 62423113Pending
- Multi-pathway Induction Of Stem Cell Differentiation With RnaApplication PCTUS2016033320Pending
- Feeder-free Derivation Of Human-induced Pluripotent Stem Cells With Synthetic Messenger RnaApplication PCTUS2015033275Pending
- Feeder-free Derivation Of Human-induced Pluripotent Stem Cells With Synthetic Messenger RnaApplication PCTUS2014040362Pending
- Novel Monomeric Yellow-green Fluorescent Protein From CephalochordateApplication PCTUS2013051911Pending
- Feeder-free Derivation Of Human-induced Pluripotent Stem Cells With Synthetic Messenger RnaApplication PCTUS2013040814Pending
- Methods Of Achieving High Specificity Of Genome EditingApplication PCTUS2019041551Pending
Recent research by its founders
- Insight into the oxygen-dependent biotransformation pathways of mercury by a facultative bacterium Raoultella terrigena TGRB320260 cites
- Multi-Scale Decomposition and Hybrid Deep Learning CEEMDAN-VMD-CNN-BiLSTM Approach for Wind Power Forecasting20257 cites
- Understanding the role of urban block morphology in innovation vitality through explainable machine learning20257 cites
Related companies, and why
- MOLECULAR TARGETING TECHNOLOGIES, INC.Similar federal contract value in Biotech · $573K in contracts
- TERA-PRINT LLCSimilar federal contract value in Biotech · $569K in contracts
- ABTERRA BIOSCIENCES, INC.Similar federal contract value in Biotech · $556K in contracts
- VITAN-BIOTECH LLCSimilar federal contract value in Biotech · $550K in contracts
- Oleolive, Inc.Similar federal contract value in Biotech · $550K in contracts
- FERROLOGIX INCSimilar federal contract value in Biotech · $548K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .